Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acet...(ite until the next quarterlyfinancial re...),Health

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter- related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Forward-Looking Statements

Cadence cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the company's interpretation of the results of recently-completed clinical trials of Acetavance(TM); expectations for completing planned and ongoing clinical trials for both Acetavance and Omigard, and whether such additional clinical trials will be sufficient to support planned New Drug Approval (NDA) applications; the potential for filing, timing and indications for use that may be included in NDAs planned for Acetavance and Omigard; the likelihood that Cadence's clinical trials of Acetavance will be consistent with clinical trials of this product candidate conducted by Cadence's licensor or others; and Cadence's commitment to complete planned development activities for its product candidates. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved.

Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Cadence's business, including, without limitation: the outcome of final analyses of data from rec
'/>"/>